Hanmi Pharmacy

Hanmi Pharmaceutical is a leading South Korean biopharmaceutical company focused on developing innovative drugs for metabolic diseases, oncology, and rare conditions. The company is globally recognized for its proprietary LAPSCOVERY platform, which extends the half-life of biologic drugs to reduce dosing frequency and improve patient compliance. Hanmi has established significant global partnerships with major firms like Merck and Genentech, and it maintains a robust portfolio of both proprietary new drugs and high-value-added generics. Its commercial success is driven by products like Amosartan and the long-acting neutropenia treatment Rolvedon. The company's R&D pipeline continues to advance next-generation treatments for MASH and obesity, positioning it as a key player in the global metabolic disease market. Hanmi also operates a significant presence in China through its subsidiary, Beijing Hanmi Pharmaceutical.